{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:51:38Z","timestamp":1781646698256,"version":"3.54.5"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We developed a framework to assess cost-utility of potential therapeutic interventions targeting reduction in cerebral infarction in aneurysmal subarachnoid hemorrhage (aSAH) patients prior to investing in high cost randomized controlled trials. We estimated the cost and Quality-Adjusted Life Years (QALYs) for 100 hypothetical aSAH patients varying the proportion of patients who develop cerebral infarction (35%, 30%, 25%, and 20%) during initial hospitalization. We estimated both cost and QALYs at 1, 5, and 30-year time. We compared the net costs of therapeutic interventions that cost $5,000, $10,000, $15,000, and $20,000 per patient to simulate costs of existing and potential therapeutic interventions. In the base case in which 35% of the 100 aSAH patients develop cerebral infarction, the total cost was $13,777,940, with total QALYs of 56.9 at 1 year. The total cost was lowest for 100 aSAH patients in the scenario where only 20% of them developed cerebral infarction with total cost estimated at $13,012,653 and QALYs of 60.8 at 1 year. A therapeutic intervention that costs $5,000 per patient (for example: enteral nimodipine, cilostazol or IV 25% humanized albumin alone or in various combinations) was cost effective at 1 year with 10% and 15% reduction in cerebral infarction (compared to the base case) and at 5 years with 5%, 10%, and 15% reduction in cerebral infarction based on a health system expense threshold (willingness to pay) of &lt;$50,000 per QALY gained. A therapeutic intervention that costs $15,000 per patient (for example: IV clazosentan) was cost effective at 5 years only with 15% reduction in cerebral infarction under willingness to pay &lt;$100,000 per QALY. We present a cost-utility framework which allows pre-trial assessment based on the cost of a therapeutic intervention and the expected magnitude of reduction in occurrence of cerebral infarction in aSAH patients.<\/jats:p>","DOI":"10.1007\/s10143-026-04201-4","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:52:12Z","timestamp":1774486332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-utility framework to evaluate therapeutic interventions targeting reduction in cerebral infarction among aneurysmal subarachnoid hemorrhage patients"],"prefix":"10.1007","volume":"49","author":[{"given":"Adnan I.","family":"Qureshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nived","family":"J. Ranjini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sandifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Beall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy N.","family":"Cassarly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron","family":"Gajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"H. Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo R.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose I.","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"4201_CR1","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1161\/STR.0000000000000436","volume":"54","author":"BL Hoh","year":"2023","unstructured":"Hoh BL, Ko NU, Amin-Hanjani S, Chou SH-Y, Cruz-Flores S, Dangayach NS et al (2023) 2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association\/American Stroke Association. Stroke 54:e314\u2013e370. https:\/\/doi.org\/10.1161\/STR.0000000000000436","journal-title":"Stroke"},{"key":"4201_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12028-023-01713-5","volume":"39","author":"MM Treggiari","year":"2023","unstructured":"Treggiari MM, Rabinstein AA, Busl KM, Caylor MM, Citerio G, Deem S et al (2023) Guidelines for the Neurocritical Care Management of Aneurysmal Subarachnoid Hemorrhage. Neurocrit Care 39:1\u201328. https:\/\/doi.org\/10.1007\/s12028-023-01713-5","journal-title":"Neurocrit Care"},{"key":"4201_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3171\/2013.3.JNS121436","volume":"119","author":"J Shen","year":"2013","unstructured":"Shen J, Pan J-W, Fan Z-X, Xiong X-X, Zhan R-Y (2013) Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials. J Neurosurg 119:180\u2013189. https:\/\/doi.org\/10.3171\/2013.3.JNS121436","journal-title":"J Neurosurg"},{"key":"4201_CR4","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1007\/s12028-021-01372-4","volume":"36","author":"AI Qureshi","year":"2022","unstructured":"Qureshi AI, Lobanova I, Huang W, Ishfaq MF, Broderick JP, Cassarly CN et al (2022) Lessons Learned from Phase II and Phase III Trials Investigating Therapeutic Agents for Cerebral Ischemia Associated with Aneurysmal Subarachnoid Hemorrhage. Neurocrit Care 36:662\u2013681. https:\/\/doi.org\/10.1007\/s12028-021-01372-4","journal-title":"Neurocrit Care"},{"key":"4201_CR5","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1161\/STROKEAHA.110.597914","volume":"42","author":"MDI Vergouwen","year":"2011","unstructured":"Vergouwen MDI, Ilodigwe D, Macdonald RL (2011) Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and -independent effects. Stroke 42:924\u2013929. https:\/\/doi.org\/10.1161\/STROKEAHA.110.597914","journal-title":"Stroke"},{"key":"4201_CR6","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1161\/STROKEAHA.111.646836","volume":"43","author":"R Dhar","year":"2012","unstructured":"Dhar R, Scalfani MT, Blackburn S, Zazulia AR, Videen T, Diringer M (2012) Relationship between angiographic vasospasm and regional hypoperfusion in aneurysmal subarachnoid hemorrhage. Stroke 43:1788\u20131794. https:\/\/doi.org\/10.1161\/STROKEAHA.111.646836","journal-title":"Stroke"},{"key":"4201_CR7","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1161\/STROKEAHA.112.669788","volume":"43","author":"KP Budohoski","year":"2012","unstructured":"Budohoski KP, Czosnyka M, Smielewski P, Kasprowicz M, Helmy A, Bulters D et al (2012) Impairment of cerebral autoregulation predicts delayed cerebral ischemia after subarachnoid hemorrhage: a prospective observational study. Stroke 43:3230\u20133237. https:\/\/doi.org\/10.1161\/STROKEAHA.112.669788","journal-title":"Stroke"},{"key":"4201_CR8","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/STROKEAHA.113.002630","volume":"45","author":"F Otite","year":"2014","unstructured":"Otite F, Mink S, Tan CO, Puri A, Zamani AA, Mehregan A et al (2014) Impaired cerebral autoregulation is associated with vasospasm and delayed cerebral ischemia in subarachnoid hemorrhage. Stroke 45:677\u2013682. https:\/\/doi.org\/10.1161\/STROKEAHA.113.002630","journal-title":"Stroke"},{"key":"4201_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/sim.1779","volume":"24","author":"EL Korn","year":"2005","unstructured":"Korn EL, Albert PS, McShane LM (2005) Assessing surrogates as trial endpoints using mixed models. Stat Med 24:163\u2013182. https:\/\/doi.org\/10.1002\/sim.1779","journal-title":"Stat Med"},{"key":"4201_CR10","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1161\/STROKEAHA.109.547331","volume":"40","author":"KT Kreiter","year":"2009","unstructured":"Kreiter KT, Mayer SA, Howard G, Knappertz V, Ilodigwe D, Sloan MA et al (2009) Sample size estimates for clinical trials of vasospasm in subarachnoid hemorrhage. Stroke 40:2362\u20132367. https:\/\/doi.org\/10.1161\/STROKEAHA.109.547331","journal-title":"Stroke"},{"key":"4201_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-3-7091-1192-5_8","volume":"115","author":"N Etminan","year":"2013","unstructured":"Etminan N, Vergouwen MDI, Macdonald RL (2013) Angiographic vasospasm versus cerebral infarction as outcome measures after aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl 115:33\u201340. https:\/\/doi.org\/10.1007\/978-3-7091-1192-5_8","journal-title":"Acta Neurochir Suppl"},{"key":"4201_CR12","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/00006123-199910000-00009","volume":"45","author":"P Karinen","year":"1999","unstructured":"Karinen P, Koivukangas P, Ohinmaa A, Koivukangas J, \u00d6hman J (1999) Cost-Effectiveness Analysis of Nimodipine Treatment after Aneurysmal Subarachnoid Hemorrhage and Surgery. Neurosurgery 45:780","journal-title":"Neurosurgery"},{"key":"4201_CR13","doi-asserted-by":"publisher","unstructured":"Briggs A (2000) Economic evaluation and clinical trials: size matters. https:\/\/doi.org\/10.1136\/bmj.321.7273.1362","DOI":"10.1136\/bmj.321.7273.1362"},{"key":"4201_CR14","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2020","unstructured":"Wouters OJ, McKee M, Luyten J (2020) Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009\u20132018. JAMA 323:844\u2013853. https:\/\/doi.org\/10.1001\/jama.2020.1166","journal-title":"JAMA"},{"key":"4201_CR15","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/jcbfm.2011.56","volume":"31","author":"MD Vergouwen","year":"2011","unstructured":"Vergouwen MD, Etminan N, Ilodigwe D, Macdonald RL (2011) Lower incidence of cerebral infarction correlates with improved functional outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 31:1545\u20131553. https:\/\/doi.org\/10.1038\/jcbfm.2011.56","journal-title":"J Cereb Blood Flow Metab"},{"key":"4201_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00701-024-05968-5","volume":"166","author":"A Lenkeit","year":"2024","unstructured":"Lenkeit A, Oppong MD, Dinger TF, G\u00fcm\u00fcs M, Rauschenbach L, Chihi M et al (2024) Risk factors for poor outcome after aneurysmal subarachnoid hemorrhage in patients with initial favorable neurological status. Acta Neurochir (Wien) 166:93. https:\/\/doi.org\/10.1007\/s00701-024-05968-5","journal-title":"Acta Neurochir (Wien)"},{"key":"4201_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/ene.13471","volume":"25","author":"NF Dengler","year":"2018","unstructured":"Dengler NF, Sommerfeld J, Diesing D, Vajkoczy P, Wolf S (2018) Prediction of cerebral infarction and patient outcome in aneurysmal subarachnoid hemorrhage: comparison of new and established radiographic, clinical and combined scores. Eur J Neurol 25:111\u2013119. https:\/\/doi.org\/10.1111\/ene.13471","journal-title":"Eur J Neurol"},{"key":"4201_CR18","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S1474-4422(11)70108-9","volume":"10","author":"RL Macdonald","year":"2011","unstructured":"Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A et al (2011) Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 10:618\u2013625. https:\/\/doi.org\/10.1016\/S1474-4422(11)70108-9","journal-title":"Lancet Neurol"},{"key":"4201_CR19","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1161\/01.STR.0000163090.59350.5a","volume":"36","author":"AA Rabinstein","year":"2005","unstructured":"Rabinstein AA, Weigand S, Atkinson JLD, Wijdicks EFM (2005) Patterns of Cerebral Infarction in Aneurysmal Subarachnoid Hemorrhage. Stroke 36:992\u2013997. https:\/\/doi.org\/10.1161\/01.STR.0000163090.59350.5a","journal-title":"Stroke"},{"key":"4201_CR20","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1161\/STROKEAHA.116.014794","volume":"47","author":"OGS Ayling","year":"2016","unstructured":"Ayling OGS, Ibrahim GM, Alotaibi NM, Gooderham PA, Macdonald RL (2016) Dissociation of Early and Delayed Cerebral Infarction After Aneurysmal Subarachnoid Hemorrhage. Stroke 47:2945\u20132951. https:\/\/doi.org\/10.1161\/STROKEAHA.116.014794","journal-title":"Stroke"},{"key":"4201_CR21","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1161\/STROKEAHA.115.010844","volume":"46","author":"GKC Wong","year":"2015","unstructured":"Wong GKC, Nung RCH, Sitt JCM, Mok VCT, Wong A, Ho FLY et al (2015) Location, Infarct Load, and 3-Month Outcomes of Delayed Cerebral Infarction After Aneurysmal Subarachnoid Hemorrhage. Stroke 46:3099\u20133104. https:\/\/doi.org\/10.1161\/STROKEAHA.115.010844","journal-title":"Stroke"},{"key":"4201_CR22","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1161\/01.STR.0000133132.76983.8e","volume":"35","author":"AA Rabinstein","year":"2004","unstructured":"Rabinstein AA, Friedman JA, Weigand SD, McClelland RL, Fulgham JR, Manno EM et al (2004) Predictors of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke 35:1862\u20131866. https:\/\/doi.org\/10.1161\/01.STR.0000133132.76983.8e","journal-title":"Stroke"},{"key":"4201_CR23","doi-asserted-by":"publisher","first-page":"e251678","DOI":"10.1001\/jamanetworkopen.2025.1678","volume":"8","author":"HS Lee","year":"2025","unstructured":"Lee HS, Sohn MK, Lee J, Kim DY, Shin Y-I, Oh G-J et al (2025) Five-Year Functional Outcomes Among Patients Surviving Aneurysmal Subarachnoid Hemorrhage. JAMA Netw Open 8:e251678. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.1678","journal-title":"JAMA Netw Open"},{"key":"4201_CR24","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1161\/STROKEAHA.115.009288","volume":"46","author":"J Huhtakangas","year":"2015","unstructured":"Huhtakangas J, Lehto H, Sepp\u00e4 K, Kivisaari R, Niemel\u00e4 M, Hernesniemi J et al (2015) Long-Term Excess Mortality After Aneurysmal Subarachnoid Hemorrhage. Stroke 46:1813\u20131818. https:\/\/doi.org\/10.1161\/STROKEAHA.115.009288","journal-title":"Stroke"},{"key":"4201_CR25","doi-asserted-by":"publisher","first-page":"106845","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106845","volume":"31","author":"B Gaastra","year":"2022","unstructured":"Gaastra B, Ren D, Alexander S, Awad IA, Blackburn S, Dor\u00e9 S et al (2022) Evidence-based interconversion of the Glasgow Outcome and modified Rankin scales: pitfalls and best practices. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc 31:106845. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2022.106845","journal-title":"J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc"},{"key":"4201_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1161\/STROKEAHA.116.014735","volume":"48","author":"TI Shireman","year":"2017","unstructured":"Shireman TI, Wang K, Saver JL, Goyal M, Bonaf\u00e9 A, Diener H-C et al (2017) Cost-Effectiveness of Solitaire Stent Retriever Thrombectomy for Acute Ischemic Stroke: Results From the SWIFT-PRIME Trial (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke). Stroke 48:379\u2013387. https:\/\/doi.org\/10.1161\/STROKEAHA.116.014735","journal-title":"Stroke"},{"key":"4201_CR27","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1212\/01.wnl.0000260967.77422.97","volume":"68","author":"GJ Hankey","year":"2007","unstructured":"Hankey GJ, Spiesser J, Hakimi Z, Bego G, Carita P, Gabriel S (2007) Rate, degree, and predictors of recovery from disability following ischemic stroke. Neurology 68:1583\u20131587. https:\/\/doi.org\/10.1212\/01.wnl.0000260967.77422.97","journal-title":"Neurology"},{"key":"4201_CR28","doi-asserted-by":"publisher","unstructured":"Porto CM, Wolman DN, Feler JR, Chuck CC, Karayi G, Torabi R et al Predictors of Skilled Nursing Facility Length of Stay and Discharge After Aneurysmal Subarachnoid Hemorrhage. Neurohospitalist 2025:19418744251323639. https:\/\/doi.org\/10.1177\/19418744251323639","DOI":"10.1177\/19418744251323639"},{"key":"4201_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.apmr.2009.10.008","volume":"91","author":"P Greebe","year":"2010","unstructured":"Greebe P, Rinkel GJ, Algra A (2010) Long-Term Outcome of Patients Discharged to a Nursing Home After Aneurysmal Subarachnoid Hemorrhage. Arch Phys Med Rehabil 91:247\u2013251. https:\/\/doi.org\/10.1016\/j.apmr.2009.10.008","journal-title":"Arch Phys Med Rehabil"},{"key":"4201_CR30","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/jon.13229","volume":"34","author":"AI Qureshi","year":"2024","unstructured":"Qureshi AI, Bhatti IA, Gillani SA, Beall J, Cassarly CN, Gajewski B et al (2024) Prevalence, trends, and outcomes of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage in the USA. J Neuroimaging 34:790\u2013798. https:\/\/doi.org\/10.1111\/jon.13229","journal-title":"J Neuroimaging"},{"key":"4201_CR31","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3171\/2010.6.JNS091486","volume":"114","author":"AI Qureshi","year":"2011","unstructured":"Qureshi AI, Vazquez G, Tariq N, Suri MFK, Lakshminarayan K, Lanzino G (2011) Impact of International Subarachnoid Aneurysm Trial results on treatment of ruptured intracranial aneurysms in the United States. Clinical article. J Neurosurg 114:834\u2013841. https:\/\/doi.org\/10.3171\/2010.6.JNS091486","journal-title":"J Neurosurg"},{"key":"4201_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12028-010-9423-5","volume":"15","author":"R Khatri","year":"2011","unstructured":"Khatri R, Tariq N, Vazquez G, Suri MFK, Ezzeddine MA, Qureshi AI (2011) Outcomes after nontraumatic subarachnoid hemorrhage at hospitals offering angioplasty for cerebral vasospasm: a national level analysis in the United States. Neurocrit Care 15:34\u201341. https:\/\/doi.org\/10.1007\/s12028-010-9423-5","journal-title":"Neurocrit Care"},{"key":"4201_CR33","first-page":"56","volume":"7","author":"DS Kainth","year":"2014","unstructured":"Kainth DS, Adil MM, Kainth HS, Dhaliwal JK, Qureshi AI (2014) Unsustainable hospital charges are incurred in the treatment of Medicare beneficiaries admitted with subarachnoid hemorrhage. J Vasc Interv Neurol 7:56\u201363","journal-title":"J Vasc Interv Neurol"},{"key":"4201_CR34","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.05.024","volume":"22","author":"F Siddiq","year":"2013","unstructured":"Siddiq F, Adil MM, Kainth D, Moen S, Qureshi AI (2013) The emergence of endovascular treatment-only centers for treatment of intracranial aneurysms in the United States. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc 22:e504\u2013510. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2013.05.024","journal-title":"J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc"},{"key":"4201_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000096542","volume":"23","author":"WC Lee","year":"2007","unstructured":"Lee WC, Christensen MC, Joshi AV, Pashos CL (2007) Long-term cost of stroke subtypes among Medicare beneficiaries. Cerebrovasc Dis Basel Switz 23:57\u201365. https:\/\/doi.org\/10.1159\/000096542","journal-title":"Cerebrovasc Dis Basel Switz"},{"key":"4201_CR36","unstructured":"Brown SG (2025) accessed July 5,. Average Cost of Skilled Nursing Facilities in 2025. SeniorLivingOrg n.d. https:\/\/www.seniorliving.org\/skilled-nursing\/cost\/"},{"key":"4201_CR37","unstructured":"Nursing Home Costs by State and Region: Updated (2025) June n.d. https:\/\/www.medicaidplanningassistance.org\/nursing-home-costs\/ (accessed July 5, 2025)"},{"key":"4201_CR38","unstructured":"Current US, Inflation Rates (2025) accessed July 5, : 2000\u20132025 n.d. https:\/\/www.usinflationcalculator.com\/inflation\/current-inflation-rates\/"},{"key":"4201_CR39","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3171\/2008.8.JNS0858","volume":"110","author":"A Maud","year":"2009","unstructured":"Maud A, Lakshminarayan K, Suri MFK, Vazquez G, Lanzino G, Qureshi AI (2009) Cost-effectiveness analysis of endovascular versus neurosurgical treatment for ruptured intracranial aneurysms in the United States. J Neurosurg 110:880\u2013886. https:\/\/doi.org\/10.3171\/2008.8.JNS0858","journal-title":"J Neurosurg"},{"key":"4201_CR40","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1161\/01.str.28.10.1876","volume":"28","author":"PJ Dorman","year":"1997","unstructured":"Dorman PJ, Waddell F, Slattery J, Dennis M, Sandercock P (1997) Is the EuroQol a valid measure of health-related quality of life after. stroke? Stroke 28:1876\u20131882. https:\/\/doi.org\/10.1161\/01.str.28.10.1876","journal-title":"stroke? Stroke"},{"key":"4201_CR41","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1046\/j.1525-1497.1997.07107.x","volume":"12","author":"JS Mandelblatt","year":"1997","unstructured":"Mandelblatt JS, Fryback DG, Weinstein MC, Russell LB, Gold MR (1997) Medicine. Assessing the Effectiveness of Health Interventions for Cost-Effectiveness Analysis. J Gen Intern Med 12:551\u2013558. https:\/\/doi.org\/10.1046\/j.1525-1497.1997.07107.x","journal-title":"J Gen Intern Med"},{"key":"4201_CR42","doi-asserted-by":"publisher","unstructured":"Zhao B, Yang H, Zheng K, Li Z, Xiong Y, Tan X et al Preoperative and postoperative predictors of long-term outcome after endovascular treatment of poor-grade aneurysmal subarachnoid hemorrhage 2016. https:\/\/doi.org\/10.3171\/2016.4.JNS152587","DOI":"10.3171\/2016.4.JNS152587"},{"key":"4201_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/M20-1392","volume":"174","author":"DJ Vanness","year":"2021","unstructured":"Vanness DJ, Lomas J, Ahn H (2021) A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States. Ann Intern Med 174:25\u201332. https:\/\/doi.org\/10.7326\/M20-1392","journal-title":"Ann Intern Med"},{"key":"4201_CR44","doi-asserted-by":"publisher","first-page":"469580221081438","DOI":"10.1177\/00469580221081438","volume":"59","author":"M Yanovskiy","year":"2022","unstructured":"Yanovskiy M, Levy ON, Shaki YY, Zigdon A, Socol Y (2022) Cost-Effectiveness Threshold for Healthcare: Justification and Quantification. Inq J Med Care Organ Provis Financ 59:469580221081438. https:\/\/doi.org\/10.1177\/00469580221081438","journal-title":"Inq J Med Care Organ Provis Financ"},{"key":"4201_CR45","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC (2014) Updating Cost-Effectiveness \u2014 The Curious Resilience of the $50,000-per-QALY Threshold. N Engl J Med 371:796\u2013797. https:\/\/doi.org\/10.1056\/NEJMp1405158","journal-title":"N Engl J Med"},{"key":"4201_CR46","unstructured":"DailyMed - (2025) accessed July 5, NIMODIPINE capsule, liquid filled n.d. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=e65d5108-22a2-4d87-a78d-15606f3cc9e2"},{"key":"4201_CR47","doi-asserted-by":"publisher","unstructured":"Dorhout Mees SM, Rinkel GJE, Feigin VL, Algra A, van den Bergh WM, Vermeulen M et al Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007;2007:CD000277. https:\/\/doi.org\/10.1002\/14651858.CD000277.pub3","DOI":"10.1002\/14651858.CD000277.pub3"},{"key":"4201_CR48","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jocn.2021.12.025","volume":"99","author":"L Li","year":"2022","unstructured":"Li L, Fu X, Qiu H, Shi P (2022) Effects of cilostazol treatment for patients with aneurysmal subarachnoid hemorrhage: A meta-analysis of 14 studies. J Clin Neurosci Off J Neurosurg Soc Australas 99:190\u2013203. https:\/\/doi.org\/10.1016\/j.jocn.2021.12.025","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"key":"4201_CR49","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1161\/STROKEAHA.121.035699","volume":"53","author":"M Dayyani","year":"2022","unstructured":"Dayyani M, Sadeghirad B, Grotta JC, Zabihyan S, Ahmadvand S, Wang Y et al (2022) Prophylactic Therapies for Morbidity and Mortality After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis of Randomized Trials. Stroke 53:1993\u20132005. https:\/\/doi.org\/10.1161\/STROKEAHA.121.035699","journal-title":"Stroke"},{"key":"4201_CR50","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1161\/STROKEAHA.111.633958","volume":"43","author":"JI Suarez","year":"2012","unstructured":"Suarez JI, Martin RH, Calvillo E, Dillon C, Bershad EM, Macdonald RL et al (2012) The Albumin in Subarachnoid Hemorrhage (ALISAH) multicenter pilot clinical trial: safety and neurologic outcomes. Stroke 43:683\u2013690. https:\/\/doi.org\/10.1161\/STROKEAHA.111.633958","journal-title":"Stroke"},{"key":"4201_CR51","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jocn.2024.06.019","volume":"126","author":"MM Al-Salihi","year":"2024","unstructured":"Al-Salihi MM, Saha R, Abd Elazim A, Helal A, Sabah Al-Jebur M, Al-Salihi Y et al (2024) The effectiveness and safety of clazosentan in treating aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis. J Clin Neurosci Off J Neurosurg Soc Australas 126:173\u2013181. https:\/\/doi.org\/10.1016\/j.jocn.2024.06.019","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"key":"4201_CR52","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1161\/STR.0000000000000436","volume":"54","author":"BL Hoh","year":"2023","unstructured":"Hoh BL, Ko NU, Amin-Hanjani S, Chou SH-Y, Cruz-Flores S, Dangayach NS et al (2023) 2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association\/American Stroke Association. Stroke 54:e314\u2013e370. https:\/\/doi.org\/10.1161\/STR.0000000000000436","journal-title":"Stroke"},{"key":"4201_CR53","doi-asserted-by":"publisher","unstructured":"Bains NK, Ngo M, Bhatti IA, Gomez FE, Arora NA, Chandrasekaran PN et al Enteral Cilostazol and High-Dose Intravenous Albumin in Aneurysmal Subarachnoid Hemorrhage Patients With Refractory Cerebral Ischemia. Cureus n d ;16:e71566. https:\/\/doi.org\/10.7759\/cureus.71566","DOI":"10.7759\/cureus.71566"},{"key":"4201_CR54","unstructured":"NADAC (National Average Drug Acquisition Cost) (2025) n.d https:\/\/data.medicaid.gov\/dataset\/f38d0706-1239-442c-a3cc-40ef1b686ac0 (accessed July 5, 2025)"},{"key":"4201_CR55","unstructured":"C2H\u0f5cCenter for Outcomes Research and Economic Evaluation for Health (2025) C2H\u0f5cCenter Outcomes Res Econ Eval Health 2025. https:\/\/c2h.niph.go.jp\/en\/"},{"key":"4201_CR56","unstructured":"[C2H2202] Clazosentan (Pivlaz) (2025) C2H\u0f5cCenter Outcomes Res Econ Eval Health n.d. https:\/\/c2h.niph.go.jp\/en\/results\/C2H2202.html"},{"key":"4201_CR57","doi-asserted-by":"publisher","unstructured":"McDougall JA, Furnback WE, Wang BCM, Mahlich J Understanding the global measurement of willingness to pay in health. J Mark Access Health Policy n d ;8:1717030. https:\/\/doi.org\/10.1080\/20016689.2020.1717030","DOI":"10.1080\/20016689.2020.1717030"},{"key":"4201_CR58","doi-asserted-by":"publisher","unstructured":"Cerebral Infarction After Subarachnoid Hemorrhage (2025) Contributes to Poor Outcome by Vasospasm-Dependent and -Independent Effects | Stroke n.d. https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/strokeaha.110.597914","DOI":"10.1161\/strokeaha.110.597914"},{"key":"4201_CR59","doi-asserted-by":"publisher","first-page":"e209607","DOI":"10.1212\/WNL.0000000000209607","volume":"103","author":"M Veldeman","year":"2024","unstructured":"Veldeman M, Rossmann T, Haeren R, Vossen LV, Weiss M, Conzen C et al (2024) Delayed Cerebral Infarction After Aneurysmal Subarachnoid Hemorrhage: Location, Distribution Patterns, Infarct Load, and Effect on Outcome. Neurology 103:e209607. https:\/\/doi.org\/10.1212\/WNL.0000000000209607","journal-title":"Neurology"},{"key":"4201_CR60","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13054-018-2151-5","volume":"22","author":"R Raj","year":"2018","unstructured":"Raj R, Bendel S, Reinikainen M, Hoppu S, Laitio R, Ala-Kokko T et al (2018) Costs, outcome and cost-effectiveness of neurocritical care: a multi-center observational study. Crit Care 22:225. https:\/\/doi.org\/10.1186\/s13054-018-2151-5","journal-title":"Crit Care"},{"key":"4201_CR61","doi-asserted-by":"publisher","first-page":"e000462","DOI":"10.1161\/SVIN.122.000462","volume":"3","author":"D Shah","year":"2023","unstructured":"Shah D, Patel U, Kellner C, Bederson J, Liang J, Dangayach NS (2023) National Trends of Interhospital Transfers for Aneurysmal Subarachnoid Hemorrhage in the United States. Stroke Vasc Interv Neurol 3:e000462. https:\/\/doi.org\/10.1161\/SVIN.122.000462","journal-title":"Stroke Vasc Interv Neurol"},{"key":"4201_CR62","doi-asserted-by":"publisher","first-page":"908609","DOI":"10.3389\/fneur.2022.908609","volume":"13","author":"VA Shah","year":"2022","unstructured":"Shah VA, Kazmi SO, Damani R, Harris AH, Hohmann SF, Calvillo E et al (2022) Regional Variability in the Care and Outcomes of Subarachnoid Hemorrhage Patients in the United States. Front Neurol 13:908609. https:\/\/doi.org\/10.3389\/fneur.2022.908609","journal-title":"Front Neurol"},{"key":"4201_CR63","unstructured":"Skilled Nursing Facility PPS | CMS n.d (2025) https:\/\/www.cms.gov\/medicare\/payment\/prospective-payment-systems\/skilled-nursing-facility-snf"},{"key":"4201_CR64","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1161\/STROKEAHA.110.586826","volume":"41","author":"R Dodel","year":"2010","unstructured":"Dodel R, Winter Y, Ringel F, Spottke A, Gharevi N, M\u00fcller I et al (2010) Cost of Illness in Subarachnoid Hemorrhage. Stroke 41:2918\u20132923. https:\/\/doi.org\/10.1161\/STROKEAHA.110.586826","journal-title":"Stroke"},{"key":"4201_CR65","doi-asserted-by":"publisher","first-page":"e231317","DOI":"10.1001\/jamahealthforum.2023.1317","volume":"4","author":"TJII Mattingly","year":"2023","unstructured":"Mattingly TJII, Anderson GF, Levy JF (2023) Comparison of Price Index Methods and Drug Price Inflation Estimates for Hepatitis C Virus Medications. JAMA Health Forum 4:e231317. https:\/\/doi.org\/10.1001\/jamahealthforum.2023.1317","journal-title":"JAMA Health Forum"},{"key":"4201_CR66","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","volume":"313","author":"MF Drummond","year":"1996","unstructured":"Drummond MF, Jefferson TO (1996) Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 313:275\u2013283. https:\/\/doi.org\/10.1136\/bmj.313.7052.275","journal-title":"BMJ"},{"key":"4201_CR67","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.280.3.275","volume":"280","author":"T Jefferson","year":"1998","unstructured":"Jefferson T, Smith R, Yee Y, Drummond M, Pratt M, Gale R (1998) Evaluating the BMJ guidelines for economic submissions: prospective audit of economic submissions to BMJ and The Lancet. JAMA 280:275\u2013277. https:\/\/doi.org\/10.1001\/jama.280.3.275","journal-title":"JAMA"},{"key":"4201_CR68","first-page":"76","volume":"68","author":"RS Kaplan","year":"2014","unstructured":"Kaplan RS (2014) Improving value with TDABC. Healthc Financ Manag J Healthc Financ Manag Assoc 68:76\u201383","journal-title":"Healthc Financ Manag J Healthc Financ Manag Assoc"},{"key":"4201_CR69","first-page":"131","volume":"82","author":"RS Kaplan","year":"2004","unstructured":"Kaplan RS, Anderson SR (2004) Time-driven activity-based costing. Harv Bus Rev 82:131\u2013138","journal-title":"Harv Bus Rev"},{"key":"4201_CR70","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13561-020-0260-8","volume":"10","author":"S Potter","year":"2020","unstructured":"Potter S, Davies C, Davies G, Rice C, Hollingworth W (2020) The use of micro-costing in economic analyses of surgical interventions: a systematic review. Health Econ Rev 10:3. https:\/\/doi.org\/10.1186\/s13561-020-0260-8","journal-title":"Health Econ Rev"},{"key":"4201_CR71","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1161\/STROKEAHA.115.009396","volume":"46","author":"J Ganesalingam","year":"2015","unstructured":"Ganesalingam J, Pizzo E, Morris S, Sunderland T, Ames D, Lobotesis K (2015) Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke. Stroke 46:2591\u20132598. https:\/\/doi.org\/10.1161\/STROKEAHA.115.009396","journal-title":"Stroke"},{"key":"4201_CR72","unstructured":"Overview | Alteplase for treating acute ischaemic stroke | Guidance | NICE (2012) https:\/\/www.nice.org.uk\/guidance\/ta264 (accessed July 17, 2025)"},{"key":"4201_CR73","unstructured":"Fulop NJ, Ramsay AI, Hunter RM, McKevitt C, Perry C, Turner SJ et al (2019) Cost-effectiveness of centralisations of acute stroke care in London and Greater Manchester A. Eval. Reconfigurations Acute Stroke Serv. Differ. Reg. Engl. Lessons Implement. Mix.-Methods Study, NIHR Journals Library"},{"key":"4201_CR74","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3171\/2012.3.JNS111266","volume":"117","author":"AA Khan","year":"2012","unstructured":"Khan AA, Chaudhry SA, Sivagnanam K, Hassan AE, Suri MFK, Qureshi AI (2012) Cost-effectiveness of carotid artery stent placement versus endarterectomy in patients with carotid artery stenosis. J Neurosurg 117:89\u201393. https:\/\/doi.org\/10.3171\/2012.3.JNS111266","journal-title":"J Neurosurg"},{"key":"4201_CR75","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/0272989X12454579","volume":"32","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB et al (2012) Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Mak Int J Soc Med Decis Mak 32:733\u2013743. https:\/\/doi.org\/10.1177\/0272989X12454579","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"key":"4201_CR76","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jval.2016.10.016","volume":"20","author":"M Hoogendoorn","year":"2017","unstructured":"Hoogendoorn M, Feenstra TL, Asukai Y, Briggs AH, Hansen RN, Leidl R et al (2017) External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. Value Health J Int Soc Pharmacoeconomics Outcomes Res 20:397\u2013403. https:\/\/doi.org\/10.1016\/j.jval.2016.10.016","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"4201_CR77","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s40273-020-00941-3","volume":"38","author":"S Lopes","year":"2020","unstructured":"Lopes S, Johansen P, Lamotte M, McEwan P, Olivieri A-V, Foos V (2020) External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions. PharmacoEconomics 38:1123\u20131133. https:\/\/doi.org\/10.1007\/s40273-020-00941-3","journal-title":"PharmacoEconomics"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04201-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-026-04201-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04201-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:52:45Z","timestamp":1781643165000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-026-04201-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4201"],"URL":"https:\/\/doi.org\/10.1007\/s10143-026-04201-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7511692\/v1","asserted-by":"object"}]},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate declarations"}}],"article-number":"305"}}